Drug Profile
MAU 868
Alternative Names: BK virus-specific antibody; MAU868Latest Information Update: 13 Nov 2022
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Developer Amplyx Pharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Human polyomavirus infections
Most Recent Events
- 05 Nov 2022 Final efficacy and adverse events data from a phase II trial in Human polyomavirus infections released by Vera Therapeutics
- 28 Oct 2022 No recent reports of development identified for phase-I development in Human-polyomavirus-infections in USA (SC)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Human-polyomavirus-infections(Prevention) in USA (IV)